The competitivness of areta in the field of research and development of novel biodrugs and innovative solutions in biotechnology has been supported by its commitment in continuous investment in this area. Since its foundation, areta dedicates about 30% of its budget to the participation to funded research projects, both at national and EU level.
To date, areta is proud of its 30% success rate in applications to EU-funded projects and 66% success rate in applications to Italian projects. This approach allowed the company to develop a unique know-how in the field of biodrugs and diagnostic solutions, as well as the ability to provide a complete set of skills to areta’s partners in funded projects, such as the philosophy of the Quality System, the multidisciplinary approach and the capability to convert research projects into industrial applications.
The result of this continuous investment is a portfolio of first-class collaborations with Academia, Research institutes, IRCCS [Scientific Institutes for Research, Hospitalization and Health Care], Italian and foreign companies, with which areta cooperates in several funded projects. Examples of these projects include: cellular therapies for bone reconstruction, regeneration of myocardial tissue, DNA vaccines for lymphomas delivered by innovative methods, highly-specific antibodies for tumor immunotherapy and enzyme replacement therapies for rare diseases.
areta’s interaction with important Centres of Excellence for various pathologies allows for the production of new, safe and effective molecules for clinical trials, thus reducing the time to market and making new therapies available to the community.